Amgen vs Hyundai: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. Hyundai was founded in 1967 by Chung Ju-yung and is led by Jose Munoz.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
Hyundai
Chung Ju-yung
Chung Ju-yung was a South Korean industrialist and the founder of the Hyundai group. He left the poor farming village where he grew up and in 1947 started a small civil engineering company.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
Hyundai
- Chung Eui-sun2019–present
Executive Chair, Hyundai Motor Group (former co-CEO of Hyundai Motor)
He successfully elevated Hyundai and Kia from budget alternatives into highly desirable, premium-leaning brands, capturing significant global EV market share.
Source - Jaehoon Chang2021–2024
President and Chief Executive Officer
As co-CEO, he drove record-breaking operating profits in 2023 by prioritizing high-margin SUVs and luxury Genesis models amid global supply chain shortages.
Source - Jose Munoz2025–present
President and Chief Executive Officer
Munoz ran Hyundai's North American business and served as global COO before becoming CEO. Since 2025 he has led the response to U.S. tariffs, the $26 billion U.S. investment plan through 2028, the hybrid expansion and the 2030 target of 5.55 million sales.
Source
Timeline: Amgen and Hyundai side by side
1967Hyundai
Hyundai Motor Company Founded
Chung Ju-yung established Hyundai Motor Company, creating the automotive arm that would become the flagship of South Korea's car industry.
1975Hyundai
Hyundai Pony
The Hyundai Pony became Korea's first mass-produced passenger car and gave Hyundai a domestic platform for exports and engineering learning.
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1986Hyundai
U.S. Market Entry
Hyundai entered the U.S. market with the Excel, rapidly building awareness as a value-oriented global automaker.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1998Hyundai
Kia Stake Acquired
Hyundai acquired a controlling stake in Kia during the Asian financial crisis, creating the basis for Hyundai Motor Group's modern platform scale.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2015Hyundai
Genesis Luxury Brand
Hyundai launched Genesis as a standalone luxury brand, supporting premiumization and higher-margin global growth.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2020Hyundai
E-GMP EV Platform
Hyundai introduced its dedicated E-GMP electric-vehicle platform, giving models such as Ioniq 5 and Ioniq 6 fast-charging and packaging advantages.
2021Hyundai
Boston Dynamics Acquisition
Hyundai Motor Group acquired a controlling stake in Boston Dynamics, adding robotics to its long-term mobility and automation strategy.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025Hyundai
Jose Munoz Becomes CEO
Jose Munoz, previously Hyundai's global COO and head of its North American business, became President and CEO effective January 1, 2025, succeeding Jaehoon Chang. He is the first non-Korean to lead the company.
2025Hyundai
Record Revenue, Tariff-Hit Profit
Hyundai reported FY2025 revenue of ~$132 billion (KRW 186.25 trillion), up 6.3%, while operating profit fell 19.5% to ~$8.14 billion (KRW 11.47 trillion) and net profit fell 21.7% to ~$7.36 billion (KRW 10.36 trillion), largely due to U.S. tariffs.
2025Hyundai
Georgia Battery Plant Raid
In September 2025, U.S. immigration agents detained hundreds of workers, many of them Korean, at the Hyundai-LG Energy Solution battery plant under construction in Georgia, delaying its opening by months.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026Hyundai
Full Ownership of Boston Dynamics
In July 2026 Hyundai Motor Group moved to buy SoftBank's remaining stake in Boston Dynamics, a deal reported at about $325 million, making the robotics company wholly owned.
2026Hyundai
2026 CEO Investor Day
At its August 2026 CEO Investor Day, Hyundai reaffirmed a 2030 target of 5.55 million global sales and detailed its $26 billion U.S. investment plan through 2028.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Questions about Amgen vs Hyundai
Who is the CEO of Amgen Inc. and Hyundai Motor Company?
Amgen Inc. is led by Robert A. Bradway and Hyundai Motor Company is led by Jose Munoz. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs Hyundai Motor Company?
Hyundai Motor Company was founded in 1967 — 13 years before Amgen Inc., which was founded in 1980. Hyundai Motor Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Amgen Inc..
How many employees does Amgen Inc. have compared to Hyundai Motor Company?
Amgen Inc. employs approximately 31,500 people, while Hyundai Motor Company employs approximately 123,000. Hyundai Motor Company has the larger workforce at 123,000 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and Hyundai Motor Company headquartered?
Amgen Inc. is headquartered in United States and Hyundai Motor Company is headquartered in South Korea. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Amgen Inc. and Hyundai Motor Company?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. Hyundai Motor Company was founded by Chung Ju-yung.
Which company has a longer operating history — Amgen Inc. or Hyundai Motor Company?
Hyundai Motor Company has been operating for approximately 59 years, making it the more established of the two companies. Amgen Inc. has been in operation for around 46 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs Hyundai overview